The clinical significance of high sensitivity HBV DNA detection for the treatment of antiviral therapy in patients with chronic hepatitis B

doi:10.3877/cma.j.issn.1674-1358.2016.01.010

Abstract

Abstract:

Objective

To investigate the clinical significance of the high sensitive HBV DNA detection for the antiviral treatment of the chronic hepatitis B (CHB) patients with HBV DNA low viral load.

Methods

Total of 160 sera specimens separated from 112 cases of quasi discontinuation group which were detected lower than the detection line (< 10³ IU/ml) and 48 cases of quasi treatment group detected by domestic reagent were tested again using COBAS Amplicor system and compared with the results of quantitative HBsAg.

Results

There were 52 (32.5%) cases with HBV DNA quantitative value > 10³ IU/ml by Amplicor COBAS system out of 160 serum samples lower than the detection line (10³ IU/ml) detected by domestic reagent, 115 (71.88%) samples were detected higher than the high sensitive HBV DNA detection line (20 IU/ml). And 72 (64.29%) cases of the withdrawal group were detected than 20 IU/ml; in the treatment group, 19 cases were detected higher than 10³ IU/ml, 43 (89.58%) cases were detected ≥ 20 IU/ml in quasi treatment group. There was a significant positive correlation between different HBV DNA load groups by COBAS reagent detection and HBsAg concentration logarithm value (P < 0.01).

Conclusions

High sensitive quantitative PCR should be furtherly conducted for HBV DNA low load patients to guide the initial application or discontinuation of nucleos(t)ide drugs.

Key words: Hepatitis B virus, Fluorescence quantitative PCR, COBAS Amplicor system, Clinical application

Guohui Shao, Xiangqin Yan, Hemin Chen, Lei Zhang, Min Sun, Yu Sun. The clinical significance of high sensitivity HBV DNA detection for the treatment of antiviral therapy in patients with chronic hepatitis B[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(01): 46-48.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2016.01.010

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2016/V10/I01/46

Figures/Tables 2

References 15

[1]	中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版)[J]. 胃肠病学和肝病学杂志,2011,20(2):197-203.
[2]	倪俊明，孙梅，吴旭平. 国产荧光定量PCR与COBAS AmpliPrep/COBAS TaqMan V 2.0检测HBV DNA结果比较[J]. 临床检验杂志,2014,32(5):398-399.
[3]	Hochberger S, Althof D, Gallegos de Schrott R, et al. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep COBAS TaqMan system[J]. J Clin Virol,2006,35(4):373-380.
[4]	李兵，王敏，徐六妹, 等. 三种HBV荧光定量PCR检测试剂的比较及结果分析[J].中华实验和临床病毒学杂志,2010,24(4):301-304.
[5]	周薇，胡爱荣. 荧光定量PCR与COBAS Taqman系统在血清HBV DNA检测中的应用及临床意义[J]. 现代实用医学,2010,22(5):520-521.
[6]	Lok AS, McMahon BJ. Chronic hepatitis B: update 2009[J]. Hepatology,2009,50(3):661-697.
[7]	慢性乙型肝炎抗病毒治疗专家委员会. 慢性乙型肝炎抗病毒治疗专家共识[J/CD]. 中国肝脏病杂志:电子版,2010,2(1):36-43.
[8]	Hann HW, Fontana RJ, Wright T, et al. A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis[J]. Liver Transpl,2003,9(1):47-56.
[9]	Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update[J]. Clin Gastroenterol Hepatol,2006,4(8):936-962.
[10]	Chu CM, Liaw YF. Hepatitis B virus-related cirrhosis: natural history and treatment[J]. Semin Liver Dis,2006,26(2):142-152.
[11]	慢性乙型肝炎特殊患者抗病毒治疗专家委员会. 慢性乙型肝炎特殊患者抗病毒治疗专家共识[J/CD]. 中华实验和临床感染病杂志:电子版,2010,4(1):92-101.
[12]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines:Management of chronic hepatitis B[J]. J Hepatol,2009,50(2):227-242. URL
[13]	Lok AS, McMahon BJ. Chronic hepatitis B[J]. Hepatology,2007,45(2):507-539.
[14]	庄辉，翁心华. 核苷(酸)类似药物治疗慢性乙型肝炎停药的探讨[J]. 中国病毒病杂志,2013,3(4):241-244.
[15]	Liang Y, Jiang J, Su M, et al. Predictors of relapse in chronic hepatitis B discontinuation of anti-riral therapy[J]. Aliment Pharmacol Ther,2011,34(3):344-352.

组别	例数	HBV DNA载量（IU/ml）
组别	例数	> 10³	20～10³	< 20	低于检测下限
拟停药组	112	33（29.46）	39（34.82）	19（16.96）	21（18.75）
拟用药组	48	19（39.58）	24（50.00）	3（6.25）	2（4.17）
合计	160	52（32.50）	63（39.38）	22（13.75）	23（14.38）

组别	例数	HBV DNA载量（IU/ml）
组别	例数	> 10³	20～10³	< 20	低于检测下限
拟停药组	112	33（29.46）	39（34.82）	19（16.96）	21（18.75）
拟用药组	48	19（39.58）	24（50.00）	3（6.25）	2（4.17）
合计	160	52（32.50）	63（39.38）	22（13.75）	23（14.38）

组别	例数	HBsAg定量（IU/ml）	r值	P值
HBV DNA> 10³ IU/ml	52	2.92 ± 0.98	0.69	< 0.01
HBV DNA 20～10³ IU/ml	63	2.65 ± 0.87	0.79	< 0.01
HBV DNA< 20 IU/ml	22	1.85 ± 0.67	0.71	< 0.01
HBV DNA低于检测下限	23	1.74 ± 0.44	0.68	< 0.01

组别	例数	HBsAg定量（IU/ml）	r值	P值
HBV DNA> 10³ IU/ml	52	2.92 ± 0.98	0.69	< 0.01
HBV DNA 20～10³ IU/ml	63	2.65 ± 0.87	0.79	< 0.01
HBV DNA< 20 IU/ml	22	1.85 ± 0.67	0.71	< 0.01
HBV DNA低于检测下限	23	1.74 ± 0.44	0.68	< 0.01

Please choose a citation manager

Content to export